PROCEPT BioRobotics (NASDAQ:PRCT) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings results on Tuesday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03, Zacks reports. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. PROCEPT BioRobotics updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

PROCEPT BioRobotics Stock Performance

Shares of PRCT traded up $0.51 during trading hours on Tuesday, reaching $35.02. 2,493,975 shares of the company traded hands, compared to its average volume of 1,041,929. The stock has a market capitalization of $1.95 billion, a P/E ratio of -22.59 and a beta of 0.99. The company has a quick ratio of 7.86, a current ratio of 9.21 and a debt-to-equity ratio of 0.13. PROCEPT BioRobotics has a 12-month low of $32.11 and a 12-month high of $103.81. The business has a fifty day moving average price of $36.66 and a 200-day moving average price of $48.17.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC raised its holdings in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares during the period. California State Teachers Retirement System lifted its holdings in shares of PROCEPT BioRobotics by 1.4% in the 2nd quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock valued at $2,848,000 after buying an additional 693 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of PROCEPT BioRobotics by 90.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after buying an additional 810 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after buying an additional 1,286 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PRCT shares. Morgan Stanley lowered their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Stephens assumed coverage on PROCEPT BioRobotics in a report on Wednesday, July 9th. They set an “overweight” rating and a $70.00 price objective for the company. BTIG Research restated a “neutral” rating on shares of PROCEPT BioRobotics in a report on Tuesday, September 16th. Truist Financial decreased their price objective on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).